BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Complement Inhibition for the Treatment of Myasthenia Gravis. Immunotargets Ther 2020;9:317-31. [PMID: 33365280 DOI: 10.2147/ITT.S261414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve 2021;64:662-9. [PMID: 34590717 DOI: 10.1002/mus.27422] [Reference Citation Analysis]
2 Stascheit F, Hotter B, Hoffmann S, Kohler S, Lehnerer S, Sputtek A, Meisel A. Calprotectin as potential novel biomarker in myasthenia gravis. J Transl Autoimmun 2021;4:100111. [PMID: 34458711 DOI: 10.1016/j.jtauto.2021.100111] [Reference Citation Analysis]
3 Mané-Damas M, Molenaar PC, Ulrichts P, Marcuse F, De Baets MH, Martinez-Martinez P, Losen M. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmun Rev 2022;:103104. [PMID: 35452851 DOI: 10.1016/j.autrev.2022.103104] [Reference Citation Analysis]
4 Vanoli F, Mantegazza R. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management. Neurotherapeutics 2022. [PMID: 35165857 DOI: 10.1007/s13311-022-01181-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Gomathy SB, Agarwal A, Vishnu VY; Department of Neurology, All India Institute of Medical Sciences, New Delhi, India, Department of Neurology, All India Institute of Medical Sciences, New Delhi, India, Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. Molecular Therapy in Myasthenia Gravis. Neurology 2022;18:49. [DOI: 10.17925/usn.2022.18.1.49] [Reference Citation Analysis]
6 Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Front Neurol 2021;12:696385. [PMID: 34795626 DOI: 10.3389/fneur.2021.696385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Plomp JJ, Huijbers MGM, Verschuuren JJGM, Borodovsky A. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies. J Neurosci Methods 2022;:109551. [PMID: 35247492 DOI: 10.1016/j.jneumeth.2022.109551] [Reference Citation Analysis]
8 Garlich J, Cinier M, Chevrel A, Perrocheau A, Eyerman DJ, Orme M, Kitten O, Scheibler L. Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation. Biomolecules 2022;12:432. [DOI: 10.3390/biom12030432] [Reference Citation Analysis]